earnings
confidence high
sentiment neutral
materiality 0.65
Clearside Biomedical Q1 net loss narrows to $8.2M; FDA agrees on Phase 3 plan for CLS-AX in wet AMD
Clearside Biomedical, Inc.
2025-Q1 EPS
reported -$0.11
vs consensus -$1.66
▲ beat
(+93.4%)
- Net loss $8.2M ($0.11/sh) vs $11.8M ($0.17) YoY; license revenue $2.3M (up from $0.2M) on Arctic Vision milestone.
- Successful End-of-Phase 2 FDA meeting; alignment on Phase 3 design for CLS-AX targeting 3-6 month flexible dosing in wet AMD.
- Partner Arctic Vision: ARCATUS approved in Australia and Singapore; NDA accepted for review in China for uveitic macular edema.
- Partner BioCryst authorized to start clinical trial for avoralstat in DME using Clearside's SCS Microinjector; initial data expected in 2025.
- Cash $13.6M at March 31, expected to fund operations into Q4 2025.